IMMUNOTHERAPY FOR CRYPTOSPORIDIUM INFECTIONS

隐孢子虫感染的免疫治疗

• 批准号: 3489287
• 负责人: JOSEPH H. CRABB
• 金额: $ 5万
• 依托单位: IMMUCELL CORPORATION
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-09-30 至 1991-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489287
• 关键词: AIDS; Cryptosporidium; antiprotozoal agents; diarrhea; drug design /synthesis /production; immunotherapy

DESCRIPTION: (Adapted from the Applicant's Abstract) The number of cases of human diarrhea attributed to Cryptosporidium parvum has increased dramatically in the last decade. In immunocompromised individuals, most notably AIDS patients, cryptosproridiosis can present as a fulminant and persistent diarrhea. There is currently no known chemotherapeutic agent that is effective against this coccidian parasite. As a result, the mortality rate for cryptosporidiosis in AIDS patients exceeds 60 percent. As the number of immunocompromised persons increases, so does the need for an effective therapy. Two independent groups have produced hyperimmune bovine anti-C. parvum colostrum which has been successful in the treatment of at least five cases of human cryptosporidiosis. There are, however, conflicting reports in the literature regarding the prophylactic and therapeutic properties of various colostrum preparations. This proposal will examine the therapeutic effects of immunoglobulin and non-immunoglobulin fractions prepared from colostrum with demonstrated efficacy in human and animal infections. Methods will also be examined for improved and expanded production of therapeutic colostrum.

描述：（根据申请人的摘要改编）案件数量 归因于隐孢子虫的人腹泻有所增加 在过去的十年中急剧。 在免疫功能低下的个体中，大多数 值得注意的是，Cryptosproridiosis可以作为暴发性和 持续的腹泻。 目前尚无已知的化学治疗剂 这是对这种球虫寄生虫有效的。 结果， 艾滋病患者隐孢子虫病的死亡率超过60％。 随着免疫功能低下的人的数量增加，需要 一种有效的疗法。 两个独立的组产生了高免疫 牛抗C。 在治疗方面已经成功的parvum乳酸 至少五例人隐孢子虫病。 但是，有 有关预防性和 各种初乳制剂的治疗特性。 这个建议 将检查免疫球蛋白和 由初乳制备的非免疫球蛋白分数 人类和动物感染的功效。 也将检查方法 改进和扩大了治疗性初乳的产生。